# A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

> **NCT06375993** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Adicet Therapeutics** · enrollment: 180 (estimated)

## Conditions studied

- Lupus Nephritis
- Autoimmune Diseases
- Systemic Sclerosis (SSc)
- Systemic Lupus Erythematosus (SLE)
- ANCA-Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myopathies
- Stiff Person Syndrome

## Interventions

- **DRUG:** ADI-001
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06375993
- **Lead sponsor:** Adicet Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375993, "A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06375993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*